Search

Your search keyword '"Sankaranarayanan, Rengaswamy"' showing total 912 results

Search Constraints

Start Over You searched for: Author "Sankaranarayanan, Rengaswamy" Remove constraint Author: "Sankaranarayanan, Rengaswamy"
912 results on '"Sankaranarayanan, Rengaswamy"'

Search Results

2. Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9–14 years versus an established quadrivalent HPV vaccine in women aged 15–26 years in India: a randomised, active-controlled, multicentre, phase 2/3 trial

3. Impact of HPV vaccination on HPV-related oral infections

5. Universal health coverage and intersectoral action for health: key messages from Disease Control Priorities, 3rd edition.

7. Accuracy of high-risk HPV DNA PCR, p16(INK4a) immunohistochemistry or the combination of both to diagnose HPV-driven oropharyngeal cancer

8. Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study

9. Patterns of care of breast cancer patients in Morocco – A study of variations in patient profile, tumour characteristics and standard of care over a decade

10. HPV DNA genotyping, HPV E6*I mRNA detection, and p16INK4a/Ki-67 staining in Belgian head and neck cancer patient specimens, collected within the HPV-AHEAD study

11. A prospective cohort study comparing efficacy of 1 dose of quadrivalent human papillomavirus vaccine to 2 and 3 doses at an average follow up of 12 years postvaccination

12. Improving access to cancer care among rural populations in India: Development of a validated tool for health system capacity assessment.

16. Current status of human papillomavirus vaccination in India's cervical cancer prevention efforts

17. Two-dose recommendation for Human Papillomavirus vaccine can be extended up to 18 years – updated evidence from Indian follow-up cohort study

18. Impact of age at vaccination and cervical HPV infection status on binding and neutralizing antibody titers at 10 years after receiving single or higher doses of quadrivalent HPV vaccine

19. Health and economic effects of introducing single-dose or two-dose human papillomavirus vaccination in India

22. Are two doses of human papillomavirus vaccine sufficient for girls aged 15–18 years? Results from a cohort study in India

25. Comprehensive Control of Human Papillomavirus Infections and Related Diseases

31. Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines

36. Costs, affordability, and feasibility of an essential package of cancer control interventions in low-income and middle-income countries: key messages from Disease Control Priorities, 3rd edition

38. World Health Organization Guidelines for treatment of cervical intraepithelial neoplasia 2–3 and screen-and-treat strategies to prevent cervical cancer

39. Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study

46. Evaluation of immune response to single dose of quadrivalent HPV vaccine at 10-year post-vaccination

47. Cancer survival in Africa, central and south America, and Asia (SURVCAN-3): a population-based benchmarking study in 32 countries

50. Report from a symposium on catalyzing primary and secondary prevention of cancer in India

Catalog

Books, media, physical & digital resources